InflaRx NV Stock Based Compensation Over Time

IFRX Stock  USD 2.36  0.05  2.16%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out InflaRx NV Performance and InflaRx NV Correlation.
For more information on how to buy InflaRx Stock please use our How to Invest in InflaRx NV guide.
  
Stock Based Compensation is likely to rise to about 4.8 M in 2024, whereas Stock Based Compensation To Revenue is likely to drop 29.53 in 2024.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InflaRx NV. If investors know InflaRx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InflaRx NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.03)
Revenue Per Share
0.002
Return On Assets
(0.22)
Return On Equity
(0.45)
The market value of InflaRx NV is measured differently than its book value, which is the value of InflaRx that is recorded on the company's balance sheet. Investors also form their own opinion of InflaRx NV's value that differs from its market value or its book value, called intrinsic value, which is InflaRx NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InflaRx NV's market value can be influenced by many factors that don't directly affect InflaRx NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InflaRx NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if InflaRx NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InflaRx NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Stock Based Compensation Analysis

Compare InflaRx NV and related stocks such as Generation Bio, Kronos Bio, and Erasca Inc Stock Based Compensation Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
GBIO3.5 M3.5 M3.5 M3.5 M3.5 M3.5 M3.5 M3.5 M3.5 M4.2 M8.4 M17.9 M24.5 M24.3 M15.2 M
KRON30 K30 K30 K30 K30 K30 K30 K30 K30 K113 K3.8 M26.2 M31.1 M25 M15.8 M
ERAS122 K122 K122 K122 K122 K122 K122 K122 K122 K122 K797 K8.3 M20.1 M26.2 M27.5 M
CCCC582 K582 K582 K582 K582 K582 K582 K582 K582 K1.6 M3.4 M21.5 M30 M27.2 M15.5 M
EWTX77 K77 K77 K77 K77 K77 K77 K77 K77 K77 K354 K4.4 M10.9 M17.6 M18.4 M
KZR128 K128 K128 K128 K128 K128 K128 K203 KMM4.9 M7.6 M14 M18.1 M19 M
FULC1.4 M1.4 M1.4 M1.4 M1.4 M1.4 M1.4 M1.4 M2.2 M4.2 M7.3 M11.1 M13.3 M14.8 M8.5 M
PASG1.5 M1.5 M1.5 M1.5 M1.5 M1.5 M1.5 M1.5 M1.5 M1.5 M14.6 M32.7 M19 M10.9 M17.3 M
ABOS174 K174 K174 K174 K174 K174 K174 K174 K174 K174 K154 K922 K3.1 M6.1 M6.5 M
INZY444 K444 K444 K444 K444 K444 K444 K444 K444 K301 K2.3 M7.2 M7.7 MM4.6 M
ELDN210 K210 K210 K238 K2.1 M2.9 MM579 K1.5 M1.3 M3.2 M7.9 M8.2 M6.5 M3.5 M
RVPH0.00.00.00.00.00.00.00.00.00.00.0106.7 K176.7 K3.4 M3.6 M
PLX3.4 M886 K7.8 M4.1 M1.2 M1.8 M988 K337 K514 K835 K3.1 M2.4 M2.1 M3.4 M2.3 M
EYPT(495.7 K)1.4 M1.3 M1.4 MM2.2 M2.5 M2.7 MM4.6 M5.5 M7.4 M14.2 M12.1 M12.7 M
SLS4.2 MM1.4 M2.5 M5.4 M1.9 M2.3 M3.2 M395 K573 K578 KM1.7 M1.4 M1.8 M
GLUE0.00.00.00.00.00.00.00.00.00.0354 K5.2 M11.7 M16.7 M17.5 M
DSGN0.00.00.00.00.00.00.00.00.00.0450 K4.7 M10.9 M13.1 M13.7 M
HOWL559 K559 K559 K559 K559 K559 K559 K559 K559 K559 K632 K4.1 M7.4 MM4.6 M
IKNA1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.8 M5.2 M7.5 M7.6 M5.1 M
STOK26 K26 K26 K26 K26 K26 K26 K26 K240 K1.9 M5.8 M16.4 M22.9 M25.3 M26.5 M

InflaRx NV and related stocks such as Generation Bio, Kronos Bio, and Erasca Inc Stock Based Compensation description

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

My Equities

My Current Equities and Potential Positions

InflaRx NV
IFRX
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationGermany
ExchangeNASDAQ Exchange
USD 2.36

Additional Tools for InflaRx Stock Analysis

When running InflaRx NV's price analysis, check to measure InflaRx NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InflaRx NV is operating at the current time. Most of InflaRx NV's value examination focuses on studying past and present price action to predict the probability of InflaRx NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move InflaRx NV's price. Additionally, you may evaluate how the addition of InflaRx NV to your portfolios can decrease your overall portfolio volatility.